Usage Examples
- PPQ is scheduled for Q3, but process validation is not closed until continued verification has a year of trending behind it.
- The observation hit our process validation package because the sampling plan never challenged blend uniformity.
- Moving to the second site means process validation has to be re-executed there, not cross-referenced from the original.
What is Process Validation (PV)?
Process Validation is the documented, data-based demonstration that a manufacturing process consistently produces drug product meeting predetermined specifications, spanning process design through routine commercial production rather than a one-time qualification exercise.
Process Validation exists because finished-product testing cannot prove a batch is good. A release test samples a fraction of units and detects only the attributes it measures, so a process that drifts between batches can still pass. Process Validation shifts the burden onto the process itself, requiring documented evidence that it reliably produces conforming product before commercial supply begins.
Process Validation covers the commercial manufacturing process for a specific product at a specific site and scale: the steps, parameters, and material attributes that drive variability in the product. Process Validation does not cover equipment and utility qualification, analytical method validation, cleaning validation, or computer system validation. Those are prerequisites that make validation data credible, and each is documented separately.
Process Validation is executed in practice as a lifecycle, the structure FDA set out in its 2011 process validation guidance: design the process, qualify it at commercial scale under an approved protocol with a justified sampling plan, then verify continuously in routine production. Process Validation packages are reviewed at inspection and summarized in the CMC section of the marketing application.
Not to be confused with
- Process Qualification (PPQ)
- process qualification is the single confirmatory stage where the designed process is demonstrated at commercial scale. Process validation is the whole lifecycle around it, so a completed PPQ campaign is a milestone inside validation, not the end of it.
- Equipment and Facility Qualification (IQ/OQ/PQ)
- qualification proves the equipment and utilities perform as specified. Process validation proves the product-forming process running on that qualified equipment yields conforming product. Qualification is a precondition for validation, never a substitute for it.
- Analytical Method Validation
- method validation proves the test measuring the product is accurate and reproducible. Process validation proves the process making the product is consistent. Validation data generated by an unvalidated method proves nothing, because the measurement itself is unqualified.
- Cleaning Validation
- cleaning validation demonstrates that residue and cross-contamination are controlled between products. Process validation addresses the product-forming steps themselves. Both live under the written-procedures obligation, but they answer different questions and carry separate protocols.
Process validation obligations in US CGMP are distributed across Part 211 rather than gathered in a single section. These are the anchors.
What you must do
- 1Establish written procedures for production and process control designed to assure the drug product has the identity, strength, quality, and purity it purports to possess21 CFR 211.100(a)
- 2Establish and follow written in-process control procedures that monitor output and validate the performance of the manufacturing processes that may be responsible for causing variability in in-process material and the drug product21 CFR 211.110(a)
- 3Validate all aseptic and sterilization processes for any product purporting to be sterile, under written procedures designed to prevent microbiological contamination21 CFR 211.113(b)
- 4Maintain records so the quality standards of each drug product can be evaluated at least annually, to determine whether specifications or manufacturing or control procedures need to change21 CFR 211.180(e)
Common mistakes
Treating three clean PPQ batches as the whole of validation
three consecutive passing batches prove the process ran three times, not that it is capable. 21 CFR 211.110(a) ties validation to the processes responsible for causing variability, so a sampling plan that never challenges those sources produces expensive documentation and an inspection finding rather than evidence.
Validating against an unqualified measurement system
validation conclusions inherit the reliability of the data behind them. When the analytical method, the sampling location, or the in-process instrument was never qualified, the entire package is unfalsifiable, and remediation usually means re-running commercial-scale batches at full cost.
Letting continued verification lapse after approval
the validated state is a claim about ongoing performance, not a permanent certificate. 21 CFR 211.180(e) requires records that support evaluating each product's quality standards at least annually; teams that stop trending after PPQ discover drift through an out-of-specification result instead of through their own data.
When This Matters
- PPQ is scheduled for Q3, but process validation is not closed until continued verification has a year of trending behind it.
- The observation hit our process validation package because the sampling plan never challenged blend uniformity.
- Moving to the second site means process validation has to be re-executed there, not cross-referenced from the original.
Frequently Asked Questions
No regulation sets a batch number. 21 CFR 211.110(a) requires control procedures that validate the performance of the manufacturing processes responsible for causing variability, without naming a count. FDA's 2011 process validation guidance expects the number of process performance qualification batches to be justified by process understanding, observed variability, and the statistical confidence required.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
Related Regulatory Intelligence
Related Actions
Sources & References
- 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals (CFR full text)
- FDA Guidance for Industry - Process Validation: General Principles and Practices (January 2011)
- FDA Current Good Manufacturing Practice (CGMP) Regulations
- ICH Quality Guidelines (Q8 Pharmaceutical Development, Q9 Quality Risk Management, Q10 Pharmaceutical Quality System)
